Abstracts

CLICK HERE TO UPLOAD YOUR ABSTRACT

The last day for abstract submission is January 14, 2011. The submission site will close at 11:59 pm PDT.  You will be notified by email by February 14, 2011 if your abstract is selected for a poster or an oral presentation.

Only ACoP 2011 registrants may submit an abstract.

Submission Guidelines: Formatting

  • Your abstract should be created in Microsoft Word, in the format of the ACoP abstract template (click to download).
  • The template has Times New Roman 10 point font, with top and left margins of 1 inch (2.54 cm) and bottom and right margins of 0.75 inches (1.91 cm). Please do not alter the font or margin size.
  • The abstract template includes instructions on the format of title, author, and affiliations.
  • The abstract should be no more than 2 pages long. Figures, tables, and symbols are allowed provided that the abstract stays within the page-length requirements and meets the formatting guidelines. Abstracts that do not comply may be rejected or require re-submission.
  • Please save your abstract as yourfirstname_yourlastname.doc. If you have more than one abstract, please name them as follows: yourfirstname_yourlastname_1.doc, yourfirstname_yourlastname_2.doc, etc. Please do NOT retain the original title of the abstract template.

You will also be asked to select a topic area to help direct your abstract to the appropriate screeners. The topics are:

PK-PD and mechanistic modeling

  • Exposure response
  • Physiologically-based modeling
  • Systems biology
  • Translational applications
  • Other

Tools and techniques

  • Experiment design
  • Meta-analysis
  • Model building
  • Model evaluation
  • Missing data
  • Non-continuous data
  • Software and algorithms
  • Statistics and biostatistics
  • Other

Special populations

  • Ethnicity
  • Geriatrics
  • Pediatrics
  • Pregnancy, maternal/fetal
  • Renal or hepatic impairment
  • Other

Clinical applications:therapeutic areas
(*) programming topics at ACoP 2011

  • Antiviral and antimicrobial
  • Diabetes
  • Heart failure (*)
  • Immune system
  • Neurodegenerative diseases (*)
  • Oncology (*)
  • Respiratory diseases
  • Other therapeutic area

Clinical applications: general

  • Benefit-risk assessment
  • Clinical outcomes
  • Clinical pharmacokinetics
  • Disease models
  • Study design/conduct
  • Other therapeutic area
  • Other

Other (you will be asked to suggest 1-2 key words)

Submission Guidelines: Content

Abstracts will be reviewed on the basis of:

• Relevance to the discipline of pharmacometrics, defined as “the science of interpreting and describing pharmacology in a quantitative fashion”, or “the science of developing and applying mathematical and statistical methods to characterize, understand and predict a drug’s pharmacokinetic, pharmacodynamic and biomarker-outcomes behavior” (Ette and Williams, 2007).

• Scientific content: abstract are expected to be scientific in nature and contain enough information to allow for scientific review (Are the methods described in sufficient detail? Does the abstract contain enough concrete evidence or results to support its conclusions? Are the results, either experimental or from computer simulation, quantitatively stated, either in table or graphical format? Alternatively, for abstracts describing a process, method or software, is the algorithm well described, has it been evaluated and are results presented? If the results are preliminary, are they characterized as such? Is the abstract purely or excessively commercial or promotional in nature?)

• Background: an appropriate level of background information should be provided to allow audience and reviewers to assess the abstract impact (Is enough background provided for the reader to understand the abstract goal? Is the literature reviewed at least to some extent and in an unbiased manner? Are citations provided?)

• Innovation: except for ENCORE presentations*, abstracts are expected to contain novel and significant information by some scientific criterion (Are the results methodologically innovative or otherwise significant? Do they shed light on certain aspects of pharmacotherapy for a particular disease? Is the methodology novel? If the methodology is not novel, is the application (to a particular problem or disease area) original? For an ENCORE submission, is the content particularly relevant to the discipline of pharmacometrics and the expected meeting audience?)

• Style: abstracts should be concisely and clearly written, including structure, language, and overall exposition (Is the abstract main goal sufficiently clear? Are the results well summarized? Are there imprecision of language or errors of syntax and/or grammar? Are measurement units reported?)

*The conference may accept a limited number of selected ENCORE presentations. Their content should be particularly relevant to the discipline of pharmacometrics and the expected meeting audience. For ENCORE presentations, submitters should disclose the previous presentation in the body of the abstract and on the poster using the following suggested format: “The results in this abstract have been previously presented in part at [conference name, venue and date] and published in the conference proceedings as abstract [number]”.

Abstracts that do not comply with the guidelines may be rejected so please take the time to conform your submission.